Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase III study of immunotherapy with recombinant interleukin-2 (IL-2) versus no further therapy in acute myeloid leukemia (AML) patients less than 60 years in first complete remission (CALGB 9720)

Phase III study of immunotherapy with recombinant interleukin-2 (IL-2) versus no further therapy in acute myeloid leukemia (AML) patients less than 60 years in first complete remission (CALGB 9720). Blood. 2006; 108:129a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.